BOYDSense
BOYDSense develops non-invasive breath analysis devices for chronic disease monitoring. Its flagship "Lassie" device uses proprietary MOx sensor arrays and embedded algorithms to estimate blood glucose from exhaled VOCs, targeting Type 2 diabetes patients, pre-diabetics, and healthcare providers.
- Company typePrivate
- Founded2015
- HeadquartersSouth San Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What BOYDSense does
BOYDSense is a Toulouse, France-based MedTech company and majority-owned subsidiary of Alpha MOS (Euronext Paris: ALNEO), developing non-invasive breath analysis devices for chronic disease monitoring. Its flagship product, the "Lassie" device, uses proprietary Metal Oxide (MOx) sensor arrays to detect and quantify Volatile Organic Compounds (VOCs) in exhaled breath, with embedded on-board algorithms translating sensor signals into blood glucose estimates. The first application targets non-invasive glucose monitoring for people with Type 2 diabetes, with a stated future pipeline extending to sepsis detection and fatty liver disease monitoring. The company has completed four clinical trials with over 370 subjects, including the BOYDSense-GM Study with 130 type 2 diabetes adults that achieved 98.7% of estimates in clinically acceptable Parkes error grid zones A/B and was published in the Journal of Diabetes Science and Technology.
The business model is a regulated medical device commercialization play: primary revenue is expected from hardware sales of the Lassie device (with associated consumables), supplemented by cloud-connected subscription or service revenue from data sharing and connected healthcare features. Pricing is not publicly disclosed. The go-to-market motion is enterprise field sales targeting healthcare providers (diabetologists, endocrinologists, hospitals) and insurance reimbursement channels, with a US subsidiary (BOYDSense, Inc.) in South San Francisco supporting North American ambitions. The company has raised approximately €9.5 million to date (€2.5M European Innovation Council grant in 2022 plus a €7M capital increase in April 2024), achieved ISO 13485 certification in March 2026, and is targeting regulatory market authorization around 2027. Current operating scale is small (1-10 employees), and the company remains pre-revenue pending regulatory clearance.
BOYDSense firmographics
Firmographics- Name
- BOYDSense
- Legal name
- BOYDSense SAS
- Website
- https://boydsense.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BOYDSense develops non-invasive breath analysis devices for chronic disease monitoring. Its flagship "Lassie" device uses proprietary MOx sensor arrays and embedded algorithms to estimate blood glucose from exhaled VOCs, targeting Type 2 diabetes patients, pre-diabetics, and healthcare providers.
- Ownership category
- akta.pro rank
BOYDSense industry classification
Industry- Product category
- Non-invasive glucose monitoring devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)
- akta.pro secondary industries
- Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI), Pulmonary Function Testing (PFT) & Spirometry Equipment (HLAHAGAH)
Keywords
Where BOYDSense is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BOYDSense business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Medical Device Sales: BOYDSense develops and plans to commercialize a non-invasive breath analysis device (Lassie) for glucose monitoring. Revenue will be generated through device sales, likely accompanied by consumables and ongoing software/cloud services for data analysis and connectivity.
- Connected Healthcare Solutions: On-board analysis algorithms delivering direct results connected with the Cloud for sharing data as part of a connected healthcare solution, potentially generating recurring software/service revenue.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
BOYDSense product offering
Product offeringCore offering
BOYDSense develops a non-invasive breath analysis medical device (named Lassie) that measures blood glucose levels by detecting and analyzing volatile organic compounds (VOCs) in exhaled breath using proprietary Metal Oxide (MOx) sensor arrays and embedded on-board algorithms. The device delivers direct results as a stand-alone unit or connected to the cloud, providing a pain-free alternative to finger-prick blood glucose monitoring for people with Type 2 diabetes.
Product overview
BOYDSense offers a breath-based health monitoring platform anchored by its Lassie device and supporting technologies. Lassie is a non-invasive glucose monitoring device that analyzes exhaled breath VOCs as a pain-free alternative to finger-prick testing. The platform includes proprietary MOx sensor arrays and breath sampling modules, with on-board analysis algorithms that deliver direct results as a stand-alone device or connected via Cloud for data sharing. The first application targets diabetes management, with future pipeline for sepsis and fatty liver disease detection and monitoring.
Differentiator
Problem solved
Functional benefit
Products and services
- Lassie Breath Glucose Monitoring Device Non-invasive breath analysis device that measures blood glucose levels through analysis of exhaled volatile organic compounds (VOCs), providing a pain-free alternative to finger-prick blood glucose monitoring. Uses proprietary MOx sensor arrays and on-board algorithms to deliver direct glucose estimates as a stand-alone device or connected to the cloud, targeted at people with Type 2 diabetes and prescribed by healthcare providers.
- Breath-based VOC Analyzer Platform Miniaturized breath analysis platform that analyzes exhaled metabolites (VOCs) for monitoring chronic diseases, combining proprietary MOx sensors, breath sampling modules, and on-board analysis algorithms. First commercial application is diabetes monitoring; future pipeline targets sepsis and fatty liver disease detection and monitoring.
Quantifiable outcome
- 98.7% of glucose estimates in clinically acceptable Parkes error grid zones A/B (T1D grid); 99.7% in T2D grid
- +4 more outcomes
Companies that use BOYDSense
Customer profileSegments4 records
Ideal customer profiles4 records
BOYDSense technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
BOYDSense partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered supporting and core.
- Seleon GmbHsupportingPartner company that provided expertise and support for achieving ISO 13485 certification for BOYDSense's quality management system.
- EurobiomedsupportingStrategic Project Council (SPC) of Eurobiomed supported BOYDSense within an EIC Accelerator application, recognizing its medical innovation.
- Toulouse University Hospital (CHU)corePromoted the 2nd BOYDSense clinical study launched in late 2021. The Diabetology, Metabolic Diseases and Nutrition research team conducted studies involving 130 patients with Type 2 diabetes. Principal investigator Prof. Pierre Gourdy led the research.
- Alpha MOScoreParent company (EuroNext: ALNEO) that founded BOYDSense as a MedTech subsidiary. Alpha MOS is a world leader in smell, taste and visual industrial instrument analyzers. BOYDSense leverages Alpha MOS technology and expertise in sensor development.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
BOYDSense competitors and assessment
Company assessmentDirect peers
- Know Labs: Public company developing non-invasive glucose monitoring using radiofrequency spectroscopy. Most direct competitor pursuing a non-invasive alternative to fingerstick/CGM, targeting similar patient populations with comparable pre-revenue/regulatory profile.
- Senseonics: Developer of Eversense, the first long-term implantable CGM (up to 180 days). Direct peer as a glucose monitoring innovator pursuing an alternative measurement modality to standard CGM with a similar long-path-to-market profile.
- Nemaura Medical: Developer of sugarBEAT, a non-invasive continuous glucose monitor worn as a patch. Direct peer in the non-invasive glucose monitoring category, also pre-commercial and targeting similar regulatory milestones.
Others
- Roche Diabetes Care: Owner of Accu-Chek and mySugr (acquired 2017); BOYDSense Board Chair Anton Kittelberger is the mySugr founder. Strategic acquirer/partner candidate in the glucose monitoring ecosystem with deep digital diabetes expertise.
Emerging players
- DiaMonTech: Berlin-based developer of non-invasive glucose monitoring using infrared spectroscopy through the skin. Emerging peer in the non-invasive glucose monitoring category with a different technical approach but identical target use case.
- AerBetic: Early-stage company developing a breath-based diabetes monitor using similar VOC detection principles. Direct emerging peer in the breath-glucose niche, pursuing the same patient use case from a smaller, US-based footprint.
Broad incumbents
- LifeScan: Maker of OneTouch blood glucose monitoring systems, formerly J&J Diabetes Care. Broad incumbent in glucose self-monitoring; BOYDSense CEO Ben Delhey previously led OneTouch launches globally, providing a direct execution playbook comparison.
- Medtronic Diabetes: Manufacturer of Guardian Connect CGM and MiniMed insulin pumps. Broad incumbent in diabetes device ecosystem; comparable as a major diabetes monitoring technology provider competing for the same patient population.
- Abbott Diabetes Care: Maker of FreeStyle Libre, the dominant flash glucose monitoring system globally. Largest installed base in glucose monitoring; BOYDSense's non-invasive approach is positioned against Abbott's expanding CGM roadmap.
- Dexcom: Global leader in continuous glucose monitoring (CGM) with the G6/G7 product family. Most directly comparable competitor in glucose monitoring; BOYDSense must beat incumbents on non-invasiveness since CGM accuracy and reimbursement are already deeply established.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BOYDSense social profiles
Digital presenceBOYDSense compliance and trust
Trust signalCompliance1 record
BOYDSense financial estimates
Financial estimateRevenue estimate
Valuation estimate
BOYDSense leadership team
Management profileNumber of profiles
Profiles7 records
BOYDSense funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BOYDSense M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BOYDSense
What does BOYDSense do?
BOYDSense develops a non-invasive breath analysis medical device (named Lassie) that measures blood glucose levels by detecting and analyzing volatile organic compounds (VOCs) in exhaled breath using proprietary Metal Oxide (MOx) sensor arrays and embedded on-board algorithms. The device delivers direct results as a stand-alone unit or connected to the cloud, providing a pain-free alternative to finger-prick blood glucose monitoring for people with Type 2 diabetes.
Is BOYDSense a public or private company?
BOYDSense is a private company. It is classified as venture growth investor backed and is currently operating.
When was BOYDSense founded?
BOYDSense was founded in 2015. It employs 1 to 10 people.
Where is BOYDSense based?
BOYDSense is headquartered in South San Francisco, United States, in the North America region.
How does BOYDSense make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are connected Healthcare Solutions.
Who are BOYDSense's main competitors?
Direct peers on record are Know Labs, Senseonics and Nemaura Medical. Roche Diabetes Care is listed as an others. Emerging players are DiaMonTech and AerBetic. Broad incumbents are LifeScan, Medtronic Diabetes, Abbott Diabetes Care and Dexcom.
Does BOYDSense have an API?
No public API is recorded for BOYDSense.
What industry is BOYDSense in?
BOYDSense's product category is Non-invasive glucose monitoring devices. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry), with a secondary code of HLAHAGAI, Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate). Its NAICS code is 334510 and its SIC code is 3841.